Skip to Main Content
Skip Nav Destination

In this chapter, we briefly present the existing hypotheses on the origin and development of Alzheimer's disease (AD) and the pathogenic genes and proteins involved in this neurological disorder. All of these can be considered potential targets for AD therapy. The next section summarises results from the application of RNAi to silence AD-associated genes, including those with mutant alleles, and describes limitations of the RNAi technology related to the delivery of siRNA effectors to the brain and the off-target effects caused by the exogenously delivered siRNAs. Finally, recent improvements in RNAi technology and perspectives for developing siRNA-based drugs for the treatment and prevention of Alzheimer's disease are presented.

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register

or Create an Account

Close Modal
Close Modal